骨桥蛋白、新蝶呤与髓过氧化物酶与卒中复发风险的相关性:SPARCL 试验 13 种生物标志物分析
本研究为 SPARCL 试验的病例-队列分析,纳入 2176 例近期卒中或 TIA 患者,评估 13 种血浆生物标志物与结局卒中的关系。调整分析显示骨桥蛋白、新蝶呤、髓过氧化物酶及脂联素与结局卒中独立相关;前三者加入 SPARCL 卒中预后工具后可改善风险分类。
要点
- 骨桥蛋白、新蝶呤、髓过氧化物酶与卒中复发独立相关。
- 三者加入 SPARCL 卒中预后工具可轻度提升风险分类能力。
- 脂联素亦与结局卒中独立相关,但未纳入最终风险分类改善分析。
核心结论
- 骨桥蛋白、新蝶呤和髓过氧化物酶与卒中复发风险独立相关,加入临床风险算法可改善风险分类。
研究设计与样本
- SPARCL 试验的病例-队列研究,纳入 2176 例近期卒中或 TIA 且无已知冠心病患者,其中 562 例发生结局卒中,1614 例随机选自未发生结局卒中者。
主要发现
- 脂蛋白相关磷脂酶 A2、单核细胞趋化蛋白-1、抵抗素、基质金属蛋白酶-9、N 末端 B 型利钠肽原、可溶性血管细胞黏附分子-1、可溶性细胞间黏附分子-1 及可溶性 CD40 配体与卒中时间无关联。
- 调整分析中,骨桥蛋白(每 SD 变化的风险比 1.362;P<0.0001)、新蝶呤(风险比 1.137;P=0.0107)、髓过氧化物酶(风险比 1.177;P=0.0022)及脂联素(风险比 1.207;P=0.0013)与结局卒中独立相关。
- 进一步调整 SPARCL 卒中预后工具-II 和治疗后,骨桥蛋白、新蝶呤和髓过氧化物酶仍与结局卒中独立相关。
- 将上述 3 种生物标志物加入 SPARCL 卒中预后工具-II 后,ROC 曲线下面积增加 0.023(P=0.015),连续净重分类改善为 29.1%(P<0.0001),综合判别改善为 42.3%(P<0.0001)。
临床怎么用
- 在近期卒中或 TIA 患者中,可考虑检测骨桥蛋白、新蝶呤和髓过氧化物酶以辅助评估卒中复发风险。
- 上述生物标志物联合 SPARCL 卒中预后工具-II 可能改善风险分层,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Established risk factors do not fully identify patients at risk for recurrent stroke. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) evaluated the effect of atorvastatin on stroke risk in patients with a recent stroke or transient ischemic attack and no known coronary heart disease. This analysis explored the relationships between 13 plasma biomarkers assessed at trial enrollment and the occurrence of outcome strokes. METHODS: We conducted a case-cohort study of 2176 participants; 562 had outcome strokes and 1614 were selected randomly from those without outcome strokes. Time to stroke was evaluated by Cox proportional hazards models. RESULTS: There was no association between time to stroke and lipoprotein-associated phospholipase A2, monocyte chemoattractant protein-1, resistin, matrix metalloproteinase-9, N-terminal fragment of pro-B-type natriuretic peptide, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, or soluble CD40 ligand. In adjusted analyses, osteopontin (hazard ratio per SD change, 1.362; P<0.0001), neopterin (hazard ratio, 1.137; P=0.0107), myeloperoxidase (hazard ratio, 1.177; P=0.0022), and adiponectin (hazard ratio, 1.207; P=0.0013) were independently associated with outcome strokes. After adjustment for the Stroke Prognostic Instrument-II and treatment, osteopontin, neopterin, and myeloperoxidase remained independently associated with outcome strokes. The addition of these 3 biomarkers to Stroke Prognostic Instrument-II increased the area under the receiver operating characteristic curve by 0.023 (P=0.015) and yielded a continuous net reclassification improvement (29.1%; P<0.0001) and an integrated discrimination improvement (42.3%; P<0.0001). CONCLUSIONS: Osteopontin, neopterin, and myeloperoxidase were independently associated with the risk of recurrent stroke and improved risk classification when added to a clinical risk algorithm. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00147602.
引用
- Ganz P, Amarenco P, Goldstein LB, et al. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017. PMID: 29114094. doi:10.1161/STROKEAHA.117.017965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。